Cell cultures of Maytenus ilicifolia Mart. are richer sources of quinone-methide triterpenoids than plant roots in natura

Autor(es)

Coppede, Juliana S. ^[1] ; Pina, Edieidia S. ^[1] ; Paz, Tiago A. ^[2] ; Fachin, Ana L. ^[1] ; Marins, Mozart A. ^[1] ; Bertoni, Bianca W. ^[1] ; Franca, Suzelei C. ^[1] ; Pereira, Ana Maria S. ^[1]

Afiliação do(s) autor(es)

^[1] Univ Ribeirao Preto, Dept Biotecnol, BR-14096380 Ribeirao Preto, SP - Brazil

^[2] Univ Estadual Paulista, Nucleo Bioensaios Biossintese & Ecofisiol Prod Na, Dept Quim Organ, Inst Quim, BR-14801970 Araraquara, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: PLANT CELL TISSUE AND ORGAN CULTURE; v. 118, n. 1, p. 33-43, JUL 2014.
• Citações Web of Science: 10

Resumo

The quinone-methide triterpenoids (QMTs) are chemotaxonomic markers of the family Celastraceae and many compounds of this class possess important anticancer and anti-inflammatory activities. However, the levels of QMTs in the roots of Celastraceous species are typically very low (ca. 0.0003 %) and commercial production by extraction from such tissues would not be commercially viable. With the aim of determining if cells cultured in vitro might provide alternative sources of these bioactive triterpenoids, we have quantified and compared the concentrations of QMTs accumulated by the roots of plants of Maytenus ilicifolia Mart. ex Reissek (Celastraceae) aged 0.5-10 years, and in callus and suspension cultures derived from a cell line that had been subcultured over a period of 10 years. Comparing plants cultivated in natura, the highest levels of QMTs were detected in the root bark of 5-year old specimens. However, cell suspensions derived from the long-term cell line retained their capacity to synthesize and accumulate QMTs, and presented levels of maytenin, 22 beta-hydroxymaytenin, celastrol and pristimerin that were, respectively, 1.96-, 2.48-, 8.85- and 3.29-times higher than those in the roots of 5-year old plants. The results presented herein open up new possibilities for the large-scale production of QMTs and for the development of novel pharmaceuticals. (AU)

• Processo FAPESP: 10/05185-0 - Produção de Triterpenos por processos biotecnológicos: fonte potencial de medicamento anticâncer
• Beneficiário: Juliana da Silva Coppede
• Modalidade de apoio: Bolsas no Brasil - Doutorado
• Processo FAPESP: 10/18132-2 - Processos biotecnológicos na produção de triterpenos: fonte potencial de medicamento anticâncer
• Beneficiário: Ana Maria Soares Pereira
• Modalidade de apoio: Auxílio à Pesquisa - Regular